Screener
Disc Medicine IRON Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Disc Medicine in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Disc Medicine’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:33 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205192
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued external research and development expenses | 686 | 280 |
| Other accrued expenses | (8,734) | (3,689) |
| Operating lease liabilities | (168) | 435 |
| Net cash used in operating activities | (62,236) | (41,376) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (93,762) | (347,250) |
| Maturities of marketable securities | 152,069 | 75,468 |
| Purchases of property and equipment | — | (851) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Disc Medicine's operating cash flow?
- Disc Medicine (IRON) reported operating cash flow of -$62.24M in Q1 2026.
- How has Disc Medicine's operating cash flow changed year-over-year?
- Disc Medicine's operating cash flow decreased by 50.4% year-over-year, from -$41.38M to -$62.24M.
- What is the long-term trend for Disc Medicine's operating cash flow?
- Over 3 years (2022 to 2025), Disc Medicine's operating cash flow has grown at a 62.2% compound annual growth rate (CAGR), from -$42.25M to -$180.39M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Disc Medicine's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude